Table 2.

Unadjusted and adjusted Cox proportional hazard model analysing the effect of levosimendan treatment on ECMO weaning failure, 30 day mortality, and long-term mortality. Hazard ratios are adjusted for all variables in the clinical confounder model (i.e. for age, sex, SAPS-3, SOFA score, hypertension, diabetes, maximal norepinephrine dose within first 24 h, left ventricular function, duration of ECMO support, and type of cardiovascular surgery). CI, confidence interval; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; SAPS-3, simplified acute physiology score 3; SOFA, sequential organ failure assessment

	Crude HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
ECMO weaning failure	0.54 (0.31–0.93)	0.03	0.41 (0.22–0.80)	0.008
30 day mortality	0.61 (0.39–0.96)	0.03	0.52 (0.30–0.89)	0.016
Long-term mortality	0.77 (0.54–1.09)	0.14	0.64 (0.42–0.98)	0.04